New, improved drugs could result from first-ever transfer of DNA information from one species of streptomyces to another

ATHENS, Ga. -- Researchers at the University of Georgia have, for the first time, successfully transferred DNA into genetically uncharacterized species of the important bacterium Streptomyces. The system is based on the use of phages (bacterial viruses) that infect these bacteria to transfer DNA from the host they are grown on to a recipient they later infect.

This procedure has several important advantages over current technology and will make it far easier (an in some cases possible) for pharmaceutical companies to develop Streoptomyces-based antibiotics and anti-cancer drugs. Results of the study were published online today in the Proceedings of the National Academy of Sciences. The print version of the research will be published on May 22.

This will allow for the first time, for example, the study and manipulation of the bleomycin biosynthetic pathway in the producing organism. Bleomycin is an important anti-cancer chemotherapeutic drug that has so far been completely refractory to genetic manipulation, said Dr. Janet Westpheling, a UGA geneticist and leader of the research team. We anticipate that the ability to get DNA into this strain of Streptomyces will lead to the production of novel bleomycins.

Westpheling, who reported on the discovery at an international meeting in Singapore in late February, gives major credit for the discovery to two students in her laboratory who were convinced that the transfer--long thought impossible by several scientists--could be successfully accomplished.

Graduate student Julie Burke and an undergraduate David Schneider (now at the department of bacteriology at the University of Wisconsin-Madison) originated the idea for the transfer system. A patent for the use of this technology in antibiotic drug discovery was issued to the University of Georgia Research Foundation in November.

Support for the work came from the National Science Foundation, Phizer Pharmaceutical Compa

Contact: Jan Westpheling
University of Georgia

Page: 1 2 3

Related biology news :

1. Travelers diarrhea not improved by restricted diet
2. New therapies under development promise improved relief for Non-Hodgkins Lymphoma cancer patients
3. ENBREL rapidly, significantly improved back pain, mobility, function in ankylosing spondylitis
4. Once weekly ENBREL significantly reduced rheumatoid arthritis pain, inflammation & improved function
5. NHLBI study finds improved heart failure survival
6. Bone marrow transplants may be improved due to the uncovering of a key mechanism
7. New NIST procedure seeks improved diagnosis of Fragile X syndrome
8. New study finds need for improved nutrition for low-income African American females
9. Researchers at Vanderbilts Free-Electron Laser Center are developing new forms of laser surgery, improved X-ray technology, and better methods for protein identification
10. UC researchers have discovered novel cell adhesion mechanism that may lead to improved treatment for sickle cell disease
11. Yale physicists first to create a squeezed state of atoms, which could lead to improved sensitivity ofnavigation systems used on planes and ships

Post Your Comments:

(Date:9/25/2019)... ... September 25, 2019 , ... ... have placed over 20,000 dental implants for a variety of procedures, including single ... and pterygoid dental implants. Dental implants offer patients permanent tooth replacement ...
(Date:9/24/2019)... ... September 23, 2019 , ... Global molecular diagnostics company ... Holotype HLA and other Omixon products will be featured among 10 posters and ... Histocompatibility and Immunogenetics (ASHI) in Pittsburgh, PA. Omixon’s Lunch Symposium on Thursday ...
(Date:9/22/2019)... ... September 20, 2019 , ... A new ... client demands for precision medicine products. The report, Lab Instrumentation Markets for ... 2018, the pharma/bio sector is the largest source of demand for laboratory instrumentation. ...
Breaking Biology News(10 mins):
(Date:10/3/2019)... , ... October 01, 2019 , ... Cheyenne is a ... Mimi, Cheyenne’s owner, owns and operates Rebel’s Run , which offers riding ... favorite amongst students and trail riding guests. Mimi describes her as her “go ...
(Date:10/3/2019)... BOSTON (PRWEB) , ... October 03, 2019 , ... Yesterday, ... 2-3, Asymmetrex founder and director, James L. Sherley, M.D., Ph.D., discussed important ... To an attendee audience including both developers and suppliers of clinical trials, in ...
(Date:9/24/2019)... (PRWEB) , ... September 24, 2019 , ... ... stem cell company, has completed training and site qualification for clinical trial sites ... of recruitment and screening of potential clinical trial participants. , Clinical trial sites ...
(Date:9/17/2019)... ... September 17, 2019 , ... Tucker, a Labrador retriever, was just a puppy ... was limping and lame on his right hip and elbow. At one year of ... “the worst case the vet had seen.” He was prescribed pain medications, both oral ...
Breaking Biology Technology:
Cached News: